- Patent Title: Anti-IL17A autoantibodies for treating or reducing the likelihood of occurrence of bone destruction associated with a chronic autoimmune or inflammatory disease
-
Application No.: US16095967Application Date: 2017-04-24
-
Publication No.: US11693003B2Publication Date: 2023-07-04
- Inventor: Pierre Miossec , Ndieme Thiam , Jean-Jacques Pin
- Applicant: Hospices Civil de Lyon , Universite Claude Bernard Lyon 1 , Dendritics
- Applicant Address: FR Lyons
- Assignee: Hospices Civil de Lyon,Universite Claude Bernard Lyon 1,Eurobio Scientific
- Current Assignee: Hospices Civil de Lyon,Universite Claude Bernard Lyon 1,Eurobio Scientific
- Current Assignee Address: FR Lyons; FR Villeurbanne; FR Courtaboeuf
- Agency: WC&F IP
- Priority: FR 53646 2016.04.25
- International Application: PCT/EP2017/059638 2017.04.24
- International Announcement: WO2017/186631A 2017.11.02
- Date entered country: 2018-10-24
- Main IPC: G01N33/53
- IPC: G01N33/53 ; G01N33/564 ; C07K16/24 ; G01N33/68
Abstract:
The present invention relates to an in vitro method for evaluating the prognosis of an autoimmune or chronic inflammatory disease in an individual, comprising the following steps: a) determining (i) the level of an anti-IL-17 autoantibody and/or (ii) the level of an [IL-17/anti-IL-17 autoantibody] complex in a biological sample of the individual, and b) comparing the level of autoantibody and/or of complex determined in step a) with a reference value, the comparison being indicative of the prognosis of an autoimmune or chronic inflammatory disease in said individual.
Public/Granted literature
- US20190137489A1 ANTIBODY ANTI IL17 Public/Granted day:2019-05-09
Information query
IPC分类:
